Companies with strong cash flow and a history of impressing Wall Street analysts may make excellent prospects for 2025; TMO, ET, and NTES are three to watch.
Intuitive Surgical, Inc. ISRG is set to report fourth-quarter 2024 earnings on Jan. 23. The Zacks Consensus Estimate for sales and earnings is pegged at $2.41 billion and $1.77 per share, respectively....
Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – How we deal with future spikes in disease cases and potential global pandemics is evolving rapidly. Not only is the...
/Thermo%20Fisher%20Scientific%20Inc_%20logo%20on%20building-by%20JHVEPhoto%20via%20iStock.jpg)
Thermo Fisher Scientific is expected to announce its fourth-quarter results later this month, and analysts predict a single-digit growth in the company’s bottom-line figure.
With talk about the sell-off of Thermo Fisher Scientific’s TMO shares by institutional investors and company insiders, market sentiment toward the company seems bearish. The stock has lost 12.7% in the...
/Thermo%20Fisher%20Scientific%20Inc_%20phone%20and%20site-by%20T_Schneider%20via%20Shutterstock.jpg)
While Thermo Fisher Scientific has underperformed the broader medical device industry recently, analysts remain optimistic about the company's future outlook.
MARC N CASPER, the Chairman & CEO of $TMO ($TMO), sold 759 shares of the company on 12-02-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.7% of their shares....
Losses for big technology stocks pulled major indexes lower on Wall Street
Despite Thermo Fisher Scientific’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
For Immediate ReleaseChicago, IL – November 19, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...